- Home
- SGN vs CERO Comparison
SGN vs CERO Comparison
Compare SGN & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- CERO
- Stock Information
- Founded
- SGN 2019
- CERO 2017
- Country
- SGN United States
- CERO United States
- Employees
- SGN N/A
- CERO N/A
- Industry
- SGN
- CERO
- Sector
- SGN
- CERO
- Exchange
- SGN Nasdaq
- CERO Nasdaq
- Market Cap
- SGN 3.8M
- CERO 3.5M
- IPO Year
- SGN 2023
- CERO N/A
- Fundamental
- Price
- SGN $1.08
- CERO $9.93
- Analyst Decision
- SGN
- CERO Strong Buy
- Analyst Count
- SGN 0
- CERO 2
- Target Price
- SGN N/A
- CERO $45.00
- AVG Volume (30 Days)
- SGN 1.3M
- CERO 3.3M
- Earning Date
- SGN 08-18-2025
- CERO 08-13-2025
- Dividend Yield
- SGN N/A
- CERO N/A
- EPS Growth
- SGN N/A
- CERO N/A
- EPS
- SGN N/A
- CERO N/A
- Revenue
- SGN $529,282.00
- CERO N/A
- Revenue This Year
- SGN N/A
- CERO N/A
- Revenue Next Year
- SGN N/A
- CERO N/A
- P/E Ratio
- SGN N/A
- CERO N/A
- Revenue Growth
- SGN 8.42
- CERO N/A
- 52 Week Low
- SGN $0.44
- CERO $6.71
- 52 Week High
- SGN $36.70
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SGN 52.82
- CERO 50.09
- Support Level
- SGN $0.92
- CERO $8.12
- Resistance Level
- SGN $1.35
- CERO $13.14
- Average True Range (ATR)
- SGN 0.17
- CERO 2.83
- MACD
- SGN -0.02
- CERO 0.39
- Stochastic Oscillator
- SGN 46.94
- CERO 19.58
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.